| INTRODUCTION
Microglia are self-renewing, long-lived cells (Bruttger et al., 2015) , which stem from a unique nonhaematopoietic yolk-sac-derived cell lineage, as indicated by elegant fate-mapping studies (Ginhoux et al., 2010; Kierdorf et al., 2013; Schulz et al., 2012) . They are critical both for developmental processes such as synaptogenesis and for the maintenance of neural homeostasis (Ekdahl, Kokaia, & Lindvall, 2009; Nikolakopoulou, Dutta, Chen, Miller, & Trapp, 2013; Ribeiro Xavier, Kress, Goldman, Lacerda de Menezes, & Nedergaard, 2015; Sellner et al., 2016; Sierra et al., 2010; Tremblay et al., 2011) .
Contributions of microglia to physiological brain function are underlined by functional deficits in neuronal connectivity and neurologic disorders in mice harboring dysfunctional microglia (Prinz & Priller, 2014) , mutant for complement or CX 3 CR1 chemokine receptors (Paolicelli et al., 2011; Schafer et al., 2012) .
In response to insult or injury, microglia are capable of acquiring diverse and complex phenotypes, allowing them to participate in cytotoxic response as well as in immune regulation or injury resolution (extensively reviewed in (Q. Li & Barres, 2018; Wolf, Boddeke, & Kettenmann, 2017; Colonna & Butovsky, 2017) . The deleterious effects of cytotoxic microglia include white and gray matter lesions in brain tissue of both patients with chronic neuroinflammatory diseases such as multiple sclerosis (MS) (Prins et al., 2015) and infants with perinatal inflammation (Dean et al., 2010; Favrais et al., 2011) . Conversely, blockage of neuron damage after acute brain injury (Faustino et al., 2011; Imai et al., 2007; Szalay et al., 2016) and promotion of remyelination in mice with myelin lesions (Butovsky et al., 2006; Miron et al., 2013; Olah et al., 2012) , reviewed in (Cherry, Olschowka, & O'Banion, 2014) , are among supportive functions of pro-regenerative microglia.
Consolidated evidence indicates that the pro-inflammatory cytokine interleukin (IL)-1β, the toll-like-receptor (TLR)-4 agonist lipopolysaccharide (LPS), the TLR-3 agonist Poly I : C, and tumor necrosis factor-α (TNFα) are potent inducers of detrimental microglial phenotype in vitro. Functionally, pro-inflammatory microglia are characterized by microbicidal, antigen-presenting and immunepotentiating abilities, through synthesis of nitric oxide (NO), chemokines, and inflammatory cytokines (Amici, Dong, & Guerau-de-Arellano, 2017) . Conversely, the anti-inflammatory cytokines IL-4 and IL-13, immune complexes, IL-1R ligands, IL-10, TGF-β, and glucocorticoids are typical agents which drive microglia toward pro-regenerative, immunomodulatory or deactivated phenotypes. Pro-regenerative microglia secrete anti-inflammatory mediators and express Arg1 instead of inducible NO synthase (iNOS), switching arginine metabolism from production of NO to ornithine and polyamines for collagen and extracellular matrix synthesis. However, detrimental and proregenerative microglia polarization in vitro is highly artificial and does not reflect the real in vivo situation where microglia activation follows a wide spectrum of phenotypes, which may be driven by diverse stimuli, as described for macrophages (Xue et al., 2014) .
Using transcriptomic and proteomic approaches Gautier et al., 2012; Hickman et al., 2013; Krasemann et al., 2017) the molecular signature of microglia in vivo has begun to be defined under physiological and pathological conditions, including amyotrophic lateral sclerosis (ALS) (Chiu et al., 2013) , multiple sclerosis (MS), Alzheimer's disease (AD) (Krasemann et al., 2017) or perinatal brain injury (Krishnan et al., 2017) . However, our understanding of the molecular mechanisms that govern transition of microglia from detrimental to proregenerative phenotypes both in vitro and in vivo remains limited. Much more is known about cellular pathways controlling polarization in macrophages, the peripheral microglia counterparts, where it is increasingly clear that metabolic activities co-define their effector state. Specifically, in peripheral macrophages, mitochondrial oxidation is a determinant of pro-regenerative polarization. Blocking oxidative metabolism abrogates anti-inflammatory macrophage function without affecting the proinflammatory state (Ghesquiere, Wong, Kuchnio, & Carmeliet, 2014) . For a detailed description of both classical and emerging pathways, including metabolic pathways, relevant for macrophage phenotypes we refer the readers to recent excellent reviews (Amici et al., 2017; Diskin & PalssonMcDermott, 2018) .
Despite the genetic profile of microglia differs profoundly from that of macrophages (Yamasaki et al., 2014) , recent evidence indicates that energy production in mitochondria may be a determinant of proregenerative/resolving differentiation also in microglia. In fact, reduced mitochondrial oxygen consumption, reduced electron transport, and mitochondrial ATP synthesis caused by deficiency in Clock (Clk)1, a mitochondrial hydroxylase that is necessary for the biosynthesis of ubiquinone (Hekimi, 2013; Lapointe & Hekimi, 2008) , has been linked to the acquisition of pro-inflammatory phenotype by microglia. Importantly, the inflammatory state of Clk1 deficient microglia relies on aerobic glycolysis, as it is abolished when glycolytic metabolism is inhibited by knocking down hexokinase 2 (HK2), a key rate-limiting enzyme for phosphorylating the glucose (J. J. Gu et al., 2018) . However, whether metabolic pathways may take central stage in inducing a repair-supportive phenotype is not yet established.
In this review, we summarize emerging strategies able to redirect microglia from detrimental to beneficial functions. As we learn more about molecular mechanisms controlling microglia effector functions, a central role of cell metabolism emerges, opening novel approaches to target microglia therapeutically.
| RECEPTOR AND CHANNELS PROMOTING ANTI-INFLAMMATORY MICROGLIA FUNCTION
Multiple brain's signaling substances converge on microglia to actively maintain or alter their functional state through a variety of neurotransmitter receptors and channels (Domercq, Vazquez-Villoldo, & Matute, 2013 ). Here we focus on receptors and channels which are involved in microglia reprogramming toward anti-inflammatory phenotype with a known mechanism of action.
| Histamine and other neurotransmitter receptors
Histamine has a well-established role as neuron-to-glia alarm signal in the brain and microglia constitutively express all four histamine receptors (H1R, H2R, H3R, and H4R) (W. Hu & Chen, 2017) . Apolloni et al. recently demonstrated that histamine counteracts proinflammatory microglia phenotype in the SOD1-G93A mouse model of ALS. They showed that histamine not only reduces expression of both NADPH oxidase 2 (NOX2), a super-oxide generating enzyme which forms reactive oxygen species (ROS), and of NF-κB, the classical transcription factor activated in pro-inflammatory microglia, but also increases the anti-inflammatory genes (IL-10, ARG1, P2Y12, CD163, and CD206) acting through H1R and H4R. Importantly, histamine exerts beneficial action only in inflammatory SOD1-G93A microglia, which are characterized by decreased H1R levels, while elicits a pro-inflammatory effect in nontransgenic cells. In support to these findings a recent work showed that histamine deficiency reduces the ramified/surveilling morphology of microglia and the production of anti-inflammatory factors in the striatum of knockout mice (Frick, Rapanelli, Abbasi, Ohtsu, & Pittenger, 2016) . With respect to the signal transduction mechanisms involved downstream of H1R and H4R activation in ALS microglia, Apolloni, and colleagues demonstrated a persistent ERK1/2 phosphorylation, which accounts for downregulation of p-NF-κB (Figure 1 ).
Among other neurotransmitter receptors controlling microglia polarization, recently reviewed by Liu et al. (Liu, Leak, & Hu, 2016) , GABA receptors are upregulated in response to brain injuries and act via NOX4 activation (Mead et al., 2012) . The endocannabinoid type 2 receptor (CB2) inhibits IL-6 and TNFα release from microglia (Bisogno & Di Marzo, 2010; Mecha et al., 2018) and increases the suppressive potency of myeloid-derived suppressor cells. Nicotinic receptors, in particular α7 receptor (Y. Sun et al., 2013; King, Gillevet, & Kabbani, 2017) , decreases p-NF-κB and its p65 subunit and inhibits p38 mitogen-activated protein kinase (p38-MAPK), a key player of inflammatory microglia response (Lawson, Dobrikova, Shveygert, & Gromeier, 2013) (Figure 1) , while upregulates antioxidant genes, promoting a pro-regenerative microglial state (Z. Han et al., 2014) . Sphingosine-1-phosphate (S1P) receptors downregulate proinflammatory cytokines and enhance pro-regenerative responses after intracerebral hemorrhage (Marfia et al., 2016; Noda, Takeuchi, Mizuno, & Suzumura, 2013) . The S1P receptor ligand FTY720 has been recently shown to attenuate microglia-mediated neuroinflammation after white matter ischemic injury and to promote oligodendrogenesis via the transcription factor signal transducer activator of transcription (STAT)3 (Qin et al., 2017) (Figure 1) , one of the STAT transcription factors that regulate cytokine (El Kasmi et al., 2006) and chemokine production. Of note, S1P is a known activator of mitochondrial function (Nema & Kumar, 2015) , suggesting a possible contribution of enhanced respiratory function to microglia phenotypic switch.
| Neuropeptide/growth factor receptors
Neuropeptides and neurotrophins acting through specific receptors are able to modulate microglial response by inhibiting the release of inflammatory mediators while favoring development of an alternative activation program (Carniglia et al., 2017; Rizzi et al., 2018) . Specifically, the melanocortins α-MSH and NDP-MSH, both exerting their actions through G protein-coupled receptors (GPCRs), were found to induce expression of the metabolic enzyme Arg1 in microglia in the retina (Kawanaka & Taylor, 2011) and in rat primary culture (Carniglia, Durand, Caruso, & Lasaga, 2013) . Arg1 induction was accompanied by enhanced expression of the nuclear receptor peroxisome proliferatoractivated receptor gamma (PPAR-γ) (Szanto et al., 2010) , and by enhanced IL-10 release (Figure 1 ), known markers of pro-regenerative microglia (see below).
The classical neurotrophin NGF, through activation of Trk-A receptors was recently shown to steer microglia toward a neuroprotective and anti-inflammatory phenotype (Rizzi et al., 2018) (Figure 1 ), being particularly effective in reverting the pro-inflammatory state of FIGURE 1 Schematic representation of receptors and signaling pathways mainly contributing to anti-inflammatory polarization of microglia. Stimulation of histamine receptors H1R and H4R induces persistent ERK1/2 phosphorylation, that leads to pNF-κB downregulation and reduces the expression of NADPH oxidase 2 (NOX2), dampening pro-inflammatory responses. Similarly, the endocannabinoid type 2 receptor (CB2) induces sustained ERK1/2 phosphorylation causing pNF-κB downregulation. GABA receptors are also involved in reducing microglia reactivity through the activation of NOX4. The nicotinic α7 receptor decreases pNF-κB and its p65 subunit and inhibits p38-MAPK. Blocking the voltage independent KCa3.1 channels and the voltage-gated Kv1.3 also results in inhibition of p38-MAPK pathway and of iNOS and COX expression. IL-10, upon binding of its receptor, suppresses pro-inflammatory cytokine production through induction of suppressor of cytokine signalling (SOCS)1 and (SOCS)3 proteins. These proteins, in turn, inhibit the cytokine-activated Janus kinase (JAK)/ STAT-1 signaling pro-inflammatory pathway. The transcription factor signal transducer and activator of transcription (STAT) 3 is instead induced by the activation of sphingosine-1-phosphate (S1P) receptors through its ligand FTY720, resulting in attenuation of microglia-mediated neuroinflammation. NGF, through activation of Trk-A receptor, reduces cytokine/chemokine secretion, microglia motility, phagocytosis, and degradative pathways. The activation of the tyrosine kinase AXL receptor by pro-resolving lipid mediators suppresses the pro-inflammatory microglial phenotype by dampening type I interferon (IFN) signaling. The melanocortins α-MSH and NDP-MSH, through G protein-coupled receptors, enhance PPAR-γ, and Arg1 expression and promote IL-10 release. Upon stimulation with IL-4, IL-4 receptor (IL-4R) induces activation of STAT-6, with consequent increase in Arg1, mannose receptor CD206 and PPAR-γ expression and with induction (and release) of anti-inflammatory cytokines like IL-4, IL-10, IL-13. For specific references see text [Color figure can be viewed at wileyonlinelibrary.com] microglia induced by β-amyloid. Importantly, the receptor signaling activated by NGF in primary culture and ex vivo not only regulates a number of microglia activities, such as cytokine/chemokine secretion, motility, phagocytosis, and degradative pathways but also controls microglia-neuron interaction, protecting neurons against Aβ-induced spine alterations and synaptic dysfunction. 
| Triggering receptor expressed on myeloid cells-2
Initial studies showed that protective microglial phenotype is induced by signals derived from apoptotic cells that activate the triggering receptor expressed on myeloid cells-2 (TREM-2). However, subsequent evidence (Krasemann et al., 2017) revealed that TREM-2 activation by apolipoprotein E (APOE), the major risk factor for AD, identified as a TREM2 ligand (Atagi et al., 2015; Bailey, DeVaux, & Farzan, 2015) , drives a neurodegenerative phenotype in microglia, characterized by suppression of major transcription factors of homeostatic microglia (PU.1, MEF2a, SMAD3, and TGF-β signaling) and overlapping to some extent the classical pro-inflammatory microglia phenotype, featured by high expression of the pro-inflammatory miRNA miR-155 (Butovsky et al., 2012) . Thus, targeting of the TREM2-APOE pathway might serve as a way to restore homeostatic microglia.
On the contrary, other studies revealed that TREM-2 deficiency, by limiting microglia activation and phagocytosis, facilitates Aβ plaque buildup, and injury of adjacent neurons in mouse model of AD (Jay, von Saucken, & Landreth, 2017; Ulrich et al., 2014;  Y. Wang et al., 2016; Yuan et al., 2016) and results in impaired elimination of supernumerary synapses during brain development (Filipello et al., 2018) . Interestingly the results coming from studies on TREM2-deficient microglia showed reduced mitochondrial mass and increased phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) (Ulland et al., 2017) , a key regulator of energy metabolism that is activated in response of low glucose and inhibits a shift in the cellular metabolism from oxidative phosphorylation to glycolysis (Hardie, 2011a (Hardie, , 2011b .
Importantly, these metabolic changes were reverted by supporting ATP synthesis, suggesting that microglia dysfunctions caused by TREM-2 deficiency depend on energetic compromise (Ghosh, Castillo, Frias, & Swanson, 2017) .
| Potassium channels
The expression of Ca2 FIGURE 2 Intracellular receptors involved in beneficial microglia polarization. PPAR-γ stimulation, by both natural and synthetic agonists (e.g., SNU-BP, pioglitazone, rosiglitazone, malibatol A, galangin), inhibits expression of inflammatory mediators, while increase the expression of the anti-inflammatory genes Arg-1, IL-4 and the fatty acid transporter CD36. Inhibition of p38-MAPK, STAT-1 and NF-κB pathways are additional mechanisms underlying the anti-inflammatory action of PPAR-γ in microglia. As in other cell types PPARs-γ may also interact with the PPAR-γ coactivator 1-alpha (PGC1α), the nuclear factor erythroid 2-related factor 1-2 (Nrf1-2), and mitochondrial transcription factors (mtTF)A, increasing mitochondrial functions. In addition in macrophages it mediates changes in lipid metabolism induced by mTOR kinase via Sema 6D [Color figure can be viewed at wileyonlinelibrary.com]
Upstream PPAR-γ expression, it has been identified msh-like homeobox-3 (MSX3), a homeobox gene particularly upregulated in pro-regenerative microglia, that acts as pivotal inducer for proregenerative microglial state (Z. Yu et al., 2015) .
| MOLECULAR MECHANISMS LINKING RECEPTOR/CHANNEL ACTIVATION TO THE BIOENERGETIC STATE OF MICROGLIA
Pharmacological analysis of microglia receptor/channel signaling cascades points to p-NF-κB, p38 -MAPK, iNOS, COX-2, and NOX2 as key inflammatory intracellular pathways downregulated by agents which dampen microglia activation under pathological stimuli. Intriguingly, emerging evidence indicates that at least p-NF-κB, iNOS and NOX2 activity are influenced by the bioenergetics state of microglia, as clearly described in a recent review (Ghosh et al., 2017) (Figure 3 ).
In fact, NADPH generated via glucose metabolism through the penthose phosphate pathway (PPP) is requisite cofactor for the pro- While SFA mainly act as pro-inflammatory stimuli (Z. Wang et al., 2012; Gao et al., 2014) , N-3 PUFAs and their metabolites have emerged as anti-inflammatory modulators of microglial functions (Laye, Nadjar, Joffre, & Bazinet, 2018) . Independent of the inflammatory challenge applied (e.g., hypoxia, interferon-y, amyloid-β), cultured microglia consistently show decreased production of pro-inflammatory factors (De Smedt-Peyrusse et al., 2008) , decreased COX2 and iNOS activity (Pettit, Varsanyi, Tadros, & Vassiliou, 2013; Zendedel et al., 2015) while exibit typical features of anti-inflammatory microglia, like CD206 surface expression and autophagy when treated with n-3 PUFAs (Chhor et al., 2013; Inoue et al., 2017) . Many in vivo studies confirm that N-3 PUFA supplementation reduces detrimental microglia function (summarized in (Laye et al., 2018) . Although microglia express a wide range of lipidsensitive receptors and lipid metabolism-related genes (Mauerer, Walczak, & Langmann, 2009; Mecha et al., 2015) , the molecular link between bioactive fatty acids and their effects in microglia has not been completely clarified yet. Emerging evidence suggests that PUFAs can drive a protective phenotype through the activation of CB2, which is among microglial receptors reprogramming microglia toward beneficial function (Guida et al., 2017; Mecha et al., 2015; Nunez et al., 2004) Table 1 ).
MiR-124 was one of the first miRNA to be linked to proregenerative microglial phenotype (Y. Sun, Luo, Guo, Su, & Liu, 2015) .
It is absent in perinatal microglia but present at high levels in adult microglia where it is strongly downregulated under inflammatory con- Metformin promotes oxidative phosphorylation through AMPK activation. Aldose reductase (AR) converts glucose into sorbitol using NADPH as a cofactor. Sorbitol, in turn, activates the phospholipase C/protein kinase C signaling pathway, resulting in downstream activation of pro-inflammatory NF-κB. By inhibiting AR, the small-molecule FMHM, Sorbinil, Zopolrestat, and Fidarestat, limit inflammatory microglia response. Furthermore, Fidarestat induces CREB phosphorylation to increase Arg1. SIRT1 activators, such as Resveratrol, inhibit the pro-inflammatory NFkB pathway and activate fatty acid metabolism. The scheme also depicts how NF-kB, iNOS, and NOX activities are influenced by the bioenergetics state of microglia. NADPH generated via glucose metabolism through PPP is a cofactor for the production of NO, by iNOS, and of superoxide, by NOX. NADH generated through glycolysis promotes dimerization of C-terminal binding protein (CtBP), preventing the corepressor activity of the monomeric form on the p300 acetylase, a NK-kB activator, with consequent activation of NF-kB transcriptional activity [Color figure can be viewed at wileyonlinelibrary.com] of CCAAT/enhancer-binding protein (C/EBP)-α (P. Zhang et al., 2004 ), one of the major transcription factor that drives pro-inflammatory microglia polarization (A. Yu et al., 2017) . Moreover, miR-124 suppresses p38-MAPK, that also has central role in coordinating inflammatory microglia responses (Lawson et al., 2013) . Of relevance for metabolic microglia reprogramming, miR-124 (Qiu et al., 2015) directly controls the bioenergetic state of the cells. Specifically, it reduces lactate production and the PPP, that supports NO and superoxide production, by targeting mRNAs encoding phosphoribosyl pyrophosphate synthetase 1 (PRPS1) and ribose-5-phosphate isomerase-A (RPIA) (Qiu et al., 2015) ; (Table 1) .
MiR200b reduces iNOS expression and NO production and limits the migratory potential of reactive microglia. Suppression of the glycolytic enzyme lactate dehydrogenase A (LDHA) and aerobic glycolysis likely underlies the miRNA action (S. Hu et al., 2016) ; (Table 1) .
MiR-146a is a microglia-enriched miRNA (Jovicic et al., 2013) induced in inflammatory microglia, which dampens inflammation by suppressing the key inflammatory proteins interleukin-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor-6 (TRAF-6) (Jayadev et al., 2013; Sharma, Verma, Kumawat, Basu, & Singh, 2015) . In addition, miR-146a may promote microglia transition ; and (c) the ability of the miR-146a to inhibit glycolytic activity (Saferding et al., 2017) and to reduce fatty acid synthesis, via FASN silencing (Guo et al., 2013; Suzuki, Kim, Ashraf, & Haider, 2010) (Table 1) .
MiR-223 is another microglia-enriched miRNA (Jovicic et al., 2013; Prada et al., 2018 ) that promotes anti-inflammatory gene expression (Table 1) . Its deficiency leads to compromised proregenerative differentiation in response to IL-4 (Zhuang et al., 2012) .
Three important inflammatory genes are validated miR-223 targets:
the pro-inflammatory regulator PBX/knotted 1 homeobox 1 (Pknox1) (Zhuang et al., 2012) , the transcription factor NFAT5, that is involved in NF-κB signaling (Lopez-Rodriguez et al., 2001 ) and RAS p21 protein activator 1 (RASA1), a crucial component of pro-inflammatory pathways in macrophage (Ying et al., 2015) . Importantly miR-223 has been shown to be required for PPAR-γ function (Zhuang et al., 2012) , linking the acquisition of pro-regenerative traits to mitochondrial glucose metabolism and fatty acid beta oxidation.
miR-181a targets the inflammatory genes IL-1α , TNF and the transcriptional factor C/EBPα but also suppresses Kruppel-like factor 6 (KLF6) (Bi et al., 2016) , a PPAR-γ inhibitor (Date et al., 2014) , thus likely favoring PPAR-γ-dependent energy metab- Table 1 ). let 7b belongs to the let 7 family of miRNAs, that dampens production and release of inflammatory molecules from microglia (Table 1) . p21-activated kinase 1 (PAK) and C/EBP have been disclosed as downstream inflammatory targets of let 7 miRNAs . However, let 7 miRNAs also serve as important mediators in energetic metabolism (Chu et al., 2015) . They reduce glucose uptake and lactate production and prompt the use of fatty acid as energy source. However, further work is required to define how let 7b impacts microglia metabolism.
MiR-21 is one of the most common anti-inflammatory miRNAs (Sheedy, 2015) . It is a negative regulator of TLR-4 signaling (FafianLabora et al., 2017), able to downregulate the expression of two essential mediators for NF-κB activation, the TLR-4 adaptor protein MyD88 and its downstream target IL1 receptor-associated kinase (IRAK) (Y. Chen et al., 2013) . In addition, miR-21 targets programmed cell death protein 4 (PDCD4) (Sheedy et al., 2010) (Table 1) .
miR-29b is upregulated in cultured microglia during neuroviral infection (Thounaojam, Kaushik, Kundu, & Basu, 2014) and suppresses immune responses to pathogens by targeting interferon-k (IFN-k) (Ma et al., 2011) . As other member of the miR-29 family, miR-29b reduces glucose uptake H. Song, Ding, Zhang, & Wang, 2018) and glycolysis (Massart et al., 2017) . However, whether miR-29 impacts glucose metabolism in a similar manner in microglia remains still unknown.
Finally, miR-125-a, known to be involved in macrophage differential activation through downregulation of TNF-α-induced protein 3 (TNFAIP3) (Graff, Dickson, Clay, McCaffrey, & Wilson, 2012) and of the inflammatory transcription factor Kruppel-like factor 13 (KLF13) , has been recently found to be upregulated in reactive microglia and in extracellular vesicles (EVs) thereof (Prada et al., 2018) . Few glycolytic enzymes, including enolase-1 (ENO-1), HK2 (F. Jin et al., 2017; C. M. Sun, Wu, Zhang, Shi, & Chen, 2017) and phosphofructokinase (PFK1) are miR-125-a validated targets (Table 1) . Consistently, miR-125-a decreases the uptake of glucose and the production of lactate, and the levels of ATP and ROS in other cell types (F. Jin et al., 2017) . Whether the miRNA suppresses glycolysis in microglia remains to be proven. (Turola, Furlan, Bianco, Matteoli, & Verderio, 2012) .
Previous findings from our group and others have shown that through their secretome MSCs re-direct microglia from detrimental toward pro-regenerative functions (Giunti et al., 2012; Zanier et al., 2014) . By investigating post-traumatic changes of microglia in mice that had received MSCs through intracerebroventricular administration, we observed an increased number of Ym1(+) protective microglia, associated with early and persistent recovery of neurological functions. MSCs, indirectly co-cultured with microglia in vitro, directly counteract the pro-inflammatory response of cells activated with inflammatory cytokines and induce persistent pro-regenerative traits (Giunti et al., 2012; Zanier et al., 2014) . More recent studies demon- Mills et al., 2016) . Extracellular succinate also exhibits pro-inflammatory activity though interaction with its specific receptor SUCNR1 and it is emerging as a biomarker of metabolic distress and inflammatory activity (Littlewood-Evans et al., 2016; E. Mills & O'Neill, 2014 (James et al., 2017) based on its ability to inhibit the kinase PDK1 and to consequently increase pyruvate dehydrogenase (PDH) activity and the flux of pyruvate into the mitochondria (Gerriets et al., 2015; Kato, Li, Chuang, & Chuang, 2007) ; (Figure 3 ). DCA has been shown to shifts glucose metabolism toward the TCA cycle/oxidative phosphorylation in T cells in mice affected by EAE (Gerriets et al., 2015) and to promote a pro-regenerative microglia/macrophages phenotype in vitro and in a peripheral inflammation model (Kato et al., 2007) . However, whether DCA shifts microglial phenotype by promoting oxidative phosphorylation has not been proven yet.
Dimethylfumarate (DMF) is an approved drug for MS, known to switch pro-inflammatory microglia to a neuroprotective state (Parodi et al., 2015) and to reduce disease progression via activation of (erythroid-derived 2)-related factor-2 (Nrf2), a transcription factor with antioxidant properties (Liddell, 2017) . DMF has been proposed to exert its therapeutic effects modulating oxidative phosphorylation, through increased levels of the TCA cycle intermediate fumarate in microglia (Tannahill, Iraci, Gaude, Frezza, & Pluchino, 2015) ; (Figure 3 ).
However, this intriguing hypothesis still remains to be validated.
Metformin is a widely used drug to treat diabetes and a wellknown activator of AMPK, already mentioned to be activated in response of low glucose and to promote oxidative phosphorylation (Hardie, 2011a (Hardie, , 2011b ; (Figure 3 ) Metformin has been recently shown to promote pro-regenerative microglial phenotype and significantly ameliorate neurobehavioral function after stroke (Q. Jin et al., 2014) and traumatic brain injury (Tao et al., 2018) , suggesting that it may be used to enhance pro-regenerative microglial function by promoting oxidative metabolism.
PPAR-γ activation is an alternative way to push oxidative metabolism in microglia, as already mentioned. PPARs-γ can be activated with thiazolidinediones (e.g., pioglitazone or rosiglitazone) a class of antidiabetic drugs proven to be effective in reducing the extent of neuroinflammation in different models of brain diseases and to attenuate neurodegeneration in patients with mild-to-moderate dementia (Heneka, Fink, & Doblhammer, 2015) .
Protective microglial function may be also promoted by pharmacological inhibitors of aldose reductase (AR), a metabolic enzyme implicated in inflammation-related diseases, that converts glucose into sorbitol using NADPH as a cofactor (Petrash, 2004) ; (Figure 3 ). The small-molecule FMHM, a natural derived AR inhibitor, was initially reported to suppress the expression of various inflammatory genes in microglia both in vitro and in vivo. Mechanistically FMHM suppresses the activity of AR-dependent phospholipase C/protein kinase C signaling, resulting in downstream inactivation of NF-κB inflammatory pathway (Zeng et al., 2013) Importantly some AR inhibitors have gone through Phase-3 clinical studies (Pandey, Srivastava, & Ramana, 2012) and Tolrestat has been approved to prevent diabetic complications (Rosa & Dias, 2014) . Francesco Bifari (Università di Milano) for useful discussion.
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